Parvoduk

RSS

Lapsed

This medicine's authorisation has lapsed

live attenuated Muscovy duck parvovirus
MedicineVeterinaryLapsed

Czech is available via eTranslation, the European Commission's machine translation service.

Translate to Czech | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for Parvoduk has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

български (BG) (279.17 KB - PDF)

Zobrazit

español (ES) (388.86 KB - PDF)

Zobrazit

čeština (CS) (432.85 KB - PDF)

Zobrazit

dansk (DA) (386.36 KB - PDF)

Zobrazit

Deutsch (DE) (392.74 KB - PDF)

Zobrazit

eesti (ET) (372.5 KB - PDF)

Zobrazit

ελληνικά (EL) (456.39 KB - PDF)

Zobrazit

français (FR) (390.28 KB - PDF)

Zobrazit

hrvatski (HR) (547.54 KB - PDF)

Zobrazit

italiano (IT) (391.31 KB - PDF)

Zobrazit

latviešu (LV) (456.12 KB - PDF)

Zobrazit

lietuvių (LT) (421.48 KB - PDF)

Zobrazit

magyar (HU) (449.76 KB - PDF)

Zobrazit

Malti (MT) (440.69 KB - PDF)

Zobrazit

Nederlands (NL) (388.36 KB - PDF)

Zobrazit

polski (PL) (432.82 KB - PDF)

Zobrazit

português (PT) (389.06 KB - PDF)

Zobrazit

română (RO) (418.94 KB - PDF)

Zobrazit

slovenčina (SK) (436.71 KB - PDF)

Zobrazit

slovenščina (SL) (428.53 KB - PDF)

Zobrazit

suomi (FI) (387.48 KB - PDF)

Zobrazit

svenska (SV) (386.11 KB - PDF)

Zobrazit

Product information

български (BG) (1.19 MB - PDF)

Zobrazit

español (ES) (804.6 KB - PDF)

Zobrazit

čeština (CS) (1.03 MB - PDF)

Zobrazit

dansk (DA) (817.13 KB - PDF)

Zobrazit

Deutsch (DE) (901.86 KB - PDF)

Zobrazit

eesti (ET) (803.72 KB - PDF)

Zobrazit

ελληνικά (EL) (1.2 MB - PDF)

Zobrazit

français (FR) (816.73 KB - PDF)

Zobrazit

hrvatski (HR) (1.23 MB - PDF)

Zobrazit

italiano (IT) (816.1 KB - PDF)

Zobrazit

latviešu (LV) (1.05 MB - PDF)

Zobrazit

lietuvių (LT) (953.35 KB - PDF)

Zobrazit

magyar (HU) (997.58 KB - PDF)

Zobrazit

Malti (MT) (1.06 MB - PDF)

Zobrazit

Nederlands (NL) (808.14 KB - PDF)

Zobrazit

polski (PL) (1.17 MB - PDF)

Zobrazit

português (PT) (803.42 KB - PDF)

Zobrazit

română (RO) (936.44 KB - PDF)

Zobrazit

slovenčina (SK) (1.06 MB - PDF)

Zobrazit

slovenščina (SL) (1.06 MB - PDF)

Zobrazit

suomi (FI) (791.59 KB - PDF)

Zobrazit

svenska (SV) (796.96 KB - PDF)

Zobrazit

Íslenska (IS) (803.26 KB - PDF)

Zobrazit

norsk (NO) (815.13 KB - PDF)

Zobrazit
Latest procedure affecting product information:R/0006
09/01/2019

български (BG) (189.97 KB - PDF)

Zobrazit

español (ES) (281.53 KB - PDF)

Zobrazit

čeština (CS) (304.72 KB - PDF)

Zobrazit

dansk (DA) (298.36 KB - PDF)

Zobrazit

Deutsch (DE) (302.28 KB - PDF)

Zobrazit

eesti (ET) (285.5 KB - PDF)

Zobrazit

ελληνικά (EL) (325.92 KB - PDF)

Zobrazit

français (FR) (335.93 KB - PDF)

Zobrazit

hrvatski (HR) (307.68 KB - PDF)

Zobrazit

italiano (IT) (299.37 KB - PDF)

Zobrazit

latviešu (LV) (340.5 KB - PDF)

Zobrazit

lietuvių (LT) (297.31 KB - PDF)

Zobrazit

magyar (HU) (303.78 KB - PDF)

Zobrazit

Malti (MT) (306.38 KB - PDF)

Zobrazit

Nederlands (NL) (313.36 KB - PDF)

Zobrazit

polski (PL) (299.63 KB - PDF)

Zobrazit

português (PT) (297.7 KB - PDF)

Zobrazit

română (RO) (312.51 KB - PDF)

Zobrazit

slovenčina (SK) (304.5 KB - PDF)

Zobrazit

slovenščina (SL) (297.92 KB - PDF)

Zobrazit

suomi (FI) (295.81 KB - PDF)

Zobrazit

svenska (SV) (293.03 KB - PDF)

Zobrazit

Íslenska (IS) (292.58 KB - PDF)

Zobrazit

norsk (NO) (298.06 KB - PDF)

Zobrazit

Product details

Name of medicine
Parvoduk
Active substance
live attenuated Muscovy duck parvovirus
International non-proprietary name (INN) or common name
live attenuated Muscovy duck parvovirus
Species
Ducks
Anatomical therapeutic chemical veterinary (ATCvet) code
QI01BD03

Pharmacotherapeutic group

  • duck parvovirus
  • Live viral vaccines
  • Immunologicals for aves

Therapeutic indication

Active immunisation of ducks to prevent mortality1 and to reduce weight loss and lesions of duck parvovirosis and Derzsy's disease.


1In absence of maternally derived antibodies.

Authorisation details

EMA product number
EMEA/V/C/002740
Marketing authorisation holder
Merial

29 Avenue Tony Garnier
69007 Lyon
France

Marketing authorisation issued
11/04/2014
Lapse of marketing authorisation
01/04/2019
Revision
2

Assessment history

This page was last updated on

Share this page